Association between CKD-MBD and hip-bone microstructures in dialysis patients

Ken Iseri1,2, Masahide Mizobuchi3, Kanji Shishido4

  • 1Department of Clinical Pharmacy, Division of Clinical Research and Development, School of Pharmacy, Showa University, Tokyo, Japan.

Clinical Kidney Journal
|August 27, 2024
PubMed

Insights

Elevated parathyroid hormone (PTH) levels, not low PTH, are linked to worsening hip bone microstructures in dialysis patients. Managing PTH is crucial for preserving bone health in this population.

Area of Science:

  • Nephrology
  • Orthopedics
  • Bone Metabolism

Background:

  • Longitudinal changes in hip bone microstructures and strength in dialysis patients are not well understood.
  • The impact of chronic kidney disease-mineral and bone disorder (CKD-MBD) biomarkers on these bone changes requires further investigation.

Purpose of the Study:

  • To examine longitudinal changes in hip bone microstructures and estimated bone strength in dialysis patients.
  • To investigate the associations between time-dependent CKD-MBD biomarkers and bone health metrics.

Main Methods:

  • Retrospective study of 276 dialysis patients over up to 2.5 years.
  • Utilized 3D-SHAPER software to assess cortical and trabecular bone compartments and bone strength indices.
  • Employed multivariate mixed models to analyze associations between CKD-MBD biomarkers and bone metrics.

Main Results:

  • Significant decreases observed in areal bone mineral density (aBMD), volumetric BMD (vBMD), cortical thickness, and cortical surface BMD (sBMD).
  • Estimated bone strength indices including cross-sectional area (CSA), CSMI, SM, and buckling ratio also deteriorated.
  • Elevated intact-parathyroid hormone (i-PTH) showed significant inverse correlations with multiple bone parameters and strength indices, while serum calcium and phosphate levels did not.

Conclusions:

  • Elevated PTH levels, rather than low PTH, are associated with the deterioration of hip bone microstructures in dialysis patients.
  • Effective management of PTH levels is critical for maintaining hip bone microstructure in patients undergoing dialysis.
Abstract